Scytonemin and methods of using thereof
AssigneesThe Regents of the University of California, Oregon State University, GlaxoSmithKline LLC
InventorsRobert S. Jacobs, Lisa A. Marshall, William H. Gerwick, Christopher Stevenson
Life of this patent
Estimating the term…
Abstract
Disclosed are compounds having a scytoneman skeleton, such as scytonemin, and methods of using thereof. Methods of using a compound having a scytoneman skeleton to inhibit, modulate, attenuate, or prevent cell-cycle progression, cell proliferation, kinase activity, or induce apoptosis are disclosed. Also disclosed are methods of treating, preventing, or inhibiting diseases and disorders associated with cell cycle progression, cell proliferation, kinase activity, tissue hyperplasia or angiogenesis, such as cancer or an inflammatory disease.
Claims19
A method of inhibiting, modulating, attenuating, or preventing cell-cycle progression, intracellular signaling, or cell proliferation of a cell comprising exposing the cell to at least one scytoneman compound.
A method of inhibiting, modulating, attenuating, or preventing a kinase, kinase activity, or phosphorylation of a substrate by a kinase comprising exposing the kinase to at least one scytoneman compound.
A method of treating, preventing, or inhibiting a disease or disorder associated with inflammation, cell cycle progression, cell proliferation, kinase activity, tissue hyperplasia or angiogenesis in a subject comprising administering at least one scytoneman compound to the subject.
A method of inducing apoptosis in a cell comprising exposing the cell to at least one scytoneman compound.
A method of treating a disease, disorder, or tissue, in a subject comprising inducing apoptosis in a target by administering at least one scytonemin compound to the subject.
A method of treating, preventing, inhibiting, attenuating or modulating inflammation related to an neurogenic inflammatory pathway in a subject comprising administering at least one scytoneman compound to the subject.
A method of treating, preventing, or inhibiting pain associated with neurogenic inflammation in a subject comprising administering at least one scytoneman compound to the subject.
Dependencies are inferred from the claim text.